{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T11:43:06Z","timestamp":1781091786251,"version":"3.54.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100009010","name":"Novartis Pharmaceuticals UK Limited","doi-asserted-by":"publisher","award":["Novartis Pharmaceuticals UK Limited"],"award-info":[{"award-number":["Novartis Pharmaceuticals UK Limited"]}],"id":[{"id":"10.13039\/100009010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI Phys"],"DOI":"10.1186\/s40658-025-00776-x","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:20:50Z","timestamp":1762521650000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Radiation exposure to families of patients following administration of 177Lu-DOTATATE for the treatment of metastatic neuroendocrine tumours"],"prefix":"10.1186","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5893-0700","authenticated-orcid":false,"given":"D.","family":"Levart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Wicks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Heraghty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Kalogianni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Mulholland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,7]]},"reference":[{"key":"776_CR1","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1200\/JCO.2007.15.2553","volume":"26","author":"DJ Kwekkeboom","year":"2008","unstructured":"Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, Feelders RA, van Aken MO, Krenning EP. Treatment with the radiolabelled somatostatin analog [177Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy and survival. J Clin Oncol. 2008;26:2124\u201330.","journal-title":"J Clin Oncol"},{"key":"776_CR2","doi-asserted-by":"publisher","first-page":"R1","DOI":"10.1530\/EJE-14-0488","volume":"172","author":"WA n der Zwan","year":"2015","unstructured":"n der Zwan WA, Bodei L, Mueller-Brand J, de Herder WW, Kvols LK, Kwekkeboom DJ. GEPNETs update: radionuclide therapy in neuroendocrine tumors. Eur J Endocrinol. 2015;172:R1\u20138.","journal-title":"Eur J Endocrinol"},{"key":"776_CR3","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg J, El-Haddad G, Wolin E, Hendifar A, et al. Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376:125\u201335.","journal-title":"N Engl J Med"},{"key":"776_CR4","unstructured":"European Medicines Agency. EMA\/524726\/2017. Lutathera. 26 September 2017. www.ema.europa.eu. [Accessed 22 August 2024]."},{"key":"776_CR5","unstructured":"National Institute of Clinical Excellence. Technology appraisal guidance [TA539]. Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours. 29 August 2018. www.nice.org.uk. [Accessed 22 August 2024]."},{"key":"776_CR6","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1097\/MNM.0000000000001780","volume":"45","author":"B Rojas","year":"2024","unstructured":"Rojas B, McGowan DR, Gear J, Smith A-L, Scott C, Craig AJ, Scuffham J, Towey D, Aldridge M, Tipping J. Nearly double the patients and dramatic changes over 14 years of UK MRT: internal dosimetry users group survey results from 2007\u20132021. Nucl Med Commun. 2024;45:16\u201323.","journal-title":"Nucl Med Commun"},{"key":"776_CR7","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1007\/s00259-012-2330-6","volume":"40","author":"JJ Zaknun","year":"2013","unstructured":"Zaknun JJ, Bodei L, Meuller-Brand J, Pavel ME, Baum RP, H\u00f6rsch D, O\u2019Dorisio MS, O\u2019Dorisiol TM, Howe JR, Cremonesi M, Kwekkeboom DJ. The joint IAEA, EANM and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2013;40:800\u201316.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"776_CR8","unstructured":"Laboratoire National Henri Becquerel. Recommended data. Available at: http:\/\/www.nucleide.org\/DDEP_WG\/DDEPdata.htm. Accessed 24 August 2017."},{"key":"776_CR9","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1007\/s002590100574","volume":"28","author":"DJ Kwekkeboom","year":"2001","unstructured":"Kwekkeboom DJ, Bakker WH, Kooij PP, Konijnenburg MW, Srinivasan A, Erio JL, et al. [177Lu-DOTA0, Tyr3] octreotate: comparison with [111In-DTPA0] octreotide in patients. Eur J Nucl Med. 2001;28:1319\u201325.","journal-title":"Eur J Nucl Med"},{"key":"776_CR10","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s12149-014-0843-8","volume":"28","author":"PJ Calais","year":"2014","unstructured":"Calais PJ, Turner JH. Radiation safety of outpatient 177Lu-octreotate radiopeptide therapy of neuroendocrine tumors. Ann Nucl Med. 2014;28:531\u20139.","journal-title":"Ann Nucl Med"},{"key":"776_CR11","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1097\/MNM.0000000000000232","volume":"36","author":"C Olmstead","year":"2015","unstructured":"Olmstead C, Cruz K, Stodilka R, Zabel P, Wolfson R. Quanitfying public radiation exposure related to lutetium-177 octreotate therapy for the development of a safe outpatient treatment protocol. Nucl Med Commun. 2015;36:129\u201334.","journal-title":"Nucl Med Commun"},{"key":"776_CR12","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40658-019-0243-1","volume":"6","author":"D Levart","year":"2019","unstructured":"Levart D, Kalogianni E, Corcoran B, Mulholland N, Vivian G. Radiation precautions for inpatient and outpatient 177Lu-DOTATATE peptide receptor radionuclide therapy of neuroendocrine tumours. EJNMMI Phys. 2019;6:7.","journal-title":"EJNMMI Phys"},{"issue":"6","key":"776_CR13","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1097\/HP.0000000000001122","volume":"177","author":"KL Nelson","year":"2019","unstructured":"Nelson KL, Sheetz MA. Radiation safety observations associated with 177Lu-Dotatate patients. Health Phys. 2019;177(6):680\u20137.","journal-title":"Health Phys"},{"key":"776_CR14","unstructured":"The Ionising Radiations. Regulations 2017 SI 2017\/1075. https:\/\/www.legislation.gov.uk\/uksi\/2017\/1075. [Accessed 25 August 2024]."},{"key":"776_CR15","unstructured":"Advanced Accelerator Applications. Your treatment with LUTATHERA\u00ae Lutetium (177Lu) oxodotreotide: LUTATHERA\u00ae Treatment Procedure Guide. March; 2023."},{"key":"776_CR16","doi-asserted-by":"crossref","unstructured":"Sanderson J, Metwaly M, Mairs W, Mayles P, Rowley L, Worral M. Medical and dental guidance notes (Second Edition): A good practice guide on all aspects of ionising radiation protection in the clinical environment: IPEM Report 113. IOP Publishing Ltd; 2024.","DOI":"10.1088\/978-0-7503-2332-1"},{"key":"776_CR17","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1007\/s002590050438","volume":"26","author":"SF Barrington","year":"1999","unstructured":"Barrington SF, O\u2019Doherty MJ, Kettle AG, Thomson WH, Mountford PJ, Burrell DN, Farrell RJ, Batchelor S, Seed P, Harding LK. Radiation exposure of the families of outpatients treated with radioiodine (iodine-131) for hyperthyroidism. Eur J Nucl Med. 1999;26:686\u201392.","journal-title":"Eur J Nucl Med"},{"key":"776_CR18","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1140\/epjp\/s13360-022-03288-0","volume":"137","author":"C Polito","year":"2022","unstructured":"Polito C, Ciucci D, Martire F, Donatiello S, Napolitano A, Pizzoferro M, Villani MF, Altini C, Garganese MC, Cannat\u00e0 V. Release criteria and exposure of caregivers and public after discharge of patients undergoing 131I-MIBG, 131I-NaI and 177Lu-DOTATATE therapies. Eur Phys J Plus. 2022;137:1088.","journal-title":"Eur Phys J Plus"},{"key":"776_CR19","unstructured":"The Ionising Radiation (Medical Exposure) Regulations. 2017, SI2017\/1322. https:\/\/www.legislation.gov.uk\/uksi\/2017\/1322. [Accessed 25 August 2024]."},{"key":"776_CR20","unstructured":"Body Thermoluminescent Dosemeter (TLD), UK Health Security Agency. https:\/\/www.ukhsa-protectionservices.org.uk\/cms\/assets\/gfx\/content\/resource_2963csb887d8d5e6.pdf. [Accessed 30\/05\/2024]."},{"key":"776_CR21","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/BF01731834","volume":"23","author":"SF Barrington","year":"1996","unstructured":"Barrington SF, Kettle AG, O\u2019Doherty MJ, Wells CP, Somer EJR, Coakley AJ. Radiation dose rates from patients receiving iodine-131 therapy for carcinoma of the thyroid. Eur J Nucl Med. 1996;23:123\u201330.","journal-title":"Eur J Nucl Med"},{"key":"776_CR22","unstructured":"European Commission. Radiation Protection NO 106: Technical Recommendations for Monitoring Individuals Occupationally Exposed to External Radiation, 2009."},{"key":"776_CR23","first-page":"1","volume":"4","author":"S Mosley","year":"2006","unstructured":"Mosley S, Currie G. Personal dosimeter use in Australian nuclear medicine practice. Internet J Nuclear Med. 2006;4:1.","journal-title":"Internet J Nuclear Med"},{"key":"776_CR24","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s40658-023-00570-7","volume":"10","author":"T Monserrat Fuertes","year":"2023","unstructured":"Monserrat Fuertes T, Santos Zorrozua B, Rode\u00f1o Ortiz de Zarate E, Peinado Montes MA. Vigil D\u00edaz C, M\u00ednguez Gabi\u00f1a P. Individualisation of radiation protection recommendations for patients treated with [177Lu]Lu-DOTA-TATE. EJNMMI Phys. 2023;10:50.","journal-title":"EJNMMI Phys"},{"key":"776_CR25","doi-asserted-by":"publisher","first-page":"021504","DOI":"10.1088\/1361-6498\/acc4d1","volume":"43","author":"D Broggio","year":"2023","unstructured":"Broggio D, C\u00e9lier D, Michel C, Isambert A. Contact restriction time after common nuclear medicine therapies: spreadsheet implementation based on Conservative retention function and individual measurements. J Radiol Prot. 2023;43:021504.","journal-title":"J Radiol Prot"}],"container-title":["EJNMMI Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40658-025-00776-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40658-025-00776-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40658-025-00776-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:20:52Z","timestamp":1762521652000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejnmmiphys.springeropen.com\/articles\/10.1186\/s40658-025-00776-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,7]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["776"],"URL":"https:\/\/doi.org\/10.1186\/s40658-025-00776-x","relation":{},"ISSN":["2197-7364"],"issn-type":[{"value":"2197-7364","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,7]]},"assertion":[{"value":"25 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Our institutional Research and Development team confirmed that this study comprised an audit and the Research Ethics Committee approval was not required. All patients and participants gave written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no conflict of interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"94"}}